The Role of Atypical Antibiotic Coverage in Community-Acquired Pneumonia
Author Information
Author(s): Hartlage Whitney PharmD, Imlay Hannah MD, MS, Spivak Emily S. MD, MHS
Primary Institution: Division of Infectious Diseases, Veteran’s Affairs Salt Lake City Health Care System, Salt Lake City, UT, USA
Hypothesis
Should atypical antibiotic coverage be routinely included in the treatment of non-severe community-acquired pneumonia?
Conclusion
Routine empiric atypical antibacterial coverage may not be necessary for all non-severe patients hospitalized with community-acquired pneumonia.
Supporting Evidence
- Current guidelines recommend a β-lactam plus a macrolide or a respiratory fluoroquinolone for non-severe pneumonia.
- Observational studies suggest that the addition of a macrolide may lower mortality compared to β-lactam alone.
- Recent studies show low rates of atypical pathogens in pneumonia cases.
Takeaway
Doctors usually give certain antibiotics for pneumonia, but this study says that not everyone needs the extra ones for atypical germs.
Methodology
This review examines existing guidelines and studies regarding the use of atypical antibiotic coverage in non-severe community-acquired pneumonia.
Potential Biases
Potential bias exists due to reliance on retrospective data and observational studies.
Limitations
The review relies on existing studies, many of which are observational and not randomized controlled trials.
Participant Demographics
The review discusses various studies involving hospitalized adults with community-acquired pneumonia.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website